Movantik is a drug owned by Valinor Pharma Llc. It is protected by 6 US drug patents filed from 2014 to 2015. Out of these, 3 drug patents are active and 3 have expired. Based on its patents and exclusivities, its generic launch date is estimated to be Apr 02, 2032. Details of Movantik's patents and their expiration are given in the table below.

A patent's expiry date may change depending upon legal activities going on that patent. Critical activities like abandoning of a patent, term extension of a patent or amendment of its claims can increase or decrease the life of a patent hence affecting its expiry date and in turn affecting the generic launch date of that drug. Tracking these ongoing activities on a patent application helps to keep an eye on the latest developments in the patent process of the drug which can give an idea of how early a drug's generic could be available. The next section provides a list of recent legal activities on Movantik's patents.

Latest Legal Activities on Movantik's Patents

Given below is the list of recent legal activities going on the following patents of Movantik.

Event	Date	Patent/Publication
Legal Activities This Week
Payment of Maintenance Fee, 8th Year, Large Entity	14 Sep, 2022	US9012469
Payment of Maintenance Fee, 12th Year, Large Entity	13 Jan, 2022	US7786133
Patent Term Extension Certificate	06 Dec, 2021	US7786133
Payment of Maintenance Fee, 12th Year, Large Entity	15 Jul, 2021	US7662365
Payment of Maintenance Fee, 8th Year, Large Entity	13 May, 2021	US8617530
Mail Certificate of Correction Memo	06 May, 2021	US9012469
Post Issue Communication - Certificate of Correction	05 May, 2021	US9012469
Certificate of Correction Memo	05 May, 2021	US9012469
Notice of Final Determination -Election Required	16 Feb, 2021	US7662365
Notice of Final Determination -Election Required	16 Feb, 2021	US7786133

While patent expiration is one way of estimating the generic date of a drug, if a patent gets invalidated somehow, the generic of the drug may arrive early. Being aware of all relevant patents can help in avoiding legal pitfalls. Given below are details of the litigation history of Movantik and ongoing litigations to help you estimate the early arrival of Movantik generic.

Movantik's Litigations

Movantik has been subject to various legal proceedings, including patent litigations. The earliest legal proceeding was initiated on Oct 15, 2015, against patent number US7786133. The petitioner Neptune Generics, LLC, challenged the validity or infringement of this patent, with NEKTAR THERAPEUTICS as the respondent. Click below to track the latest information on how companies are challenging Movantik's patents.

Patent	Proceeding Filing Date	Status	Respondent	Petitioner
Live updates
US7786133	October, 2015	Terminated-Denied	NEKTAR THERAPEUTICS	Neptune Generics, LLC

FDA has granted some exclusivities to Movantik. Till the time these exclusivities are active, no other company can market a generic or bioequivalent version of Movantik, regardless of the status of it's patents. These exclusivities hence play a crucial role in delaying the generic launch. Given below are details of the exclusivities granted to Movantik.

Stay ahead of others in designing the generic launch strategy of these 5 blockbuster drugs expiring in next 5 years.

Get the exclusive patent insights now. Don't be the last to know.

Download Report

Several oppositions have been filed on Movantik's European patents. EP oppositions can significantly impact the timeline for the generic launch of drugs. If an opposition results in the revocation or amendment of a patent, it can shorten the exclusivity period of the original drug. This can lead to an earlier entry of generic versions into the market. To help you estimate the potential early arrival of Movantik's generic, the next section provides detailed information on ongoing and past EP oppositions related to Movantik patents.

Movantik's oppositions filed in EPO

Movantik has faced multiple oppositions in the European Patent Office. The earliest opposition was filed on Oct 22, 2014, by Generics (Uk) Ltd (Trading As Mylan). This opposition was filed on patent number EP04814802A. Click below to reveal the latest opposition data.

Application	Filing Date	Opposition Party	Legal Status
Live updates
EP11829686A	Sep, 2016	ABG Patentes, S.L.	Patent maintained as amended
EP11829686A	Sep, 2016	Stada-Arzneimittel Aktiengesellschaft	Patent maintained as amended
EP11829686A	Sep, 2016	Generics [UK] Limited	Patent maintained as amended
EP04814802A	Oct, 2014	Generics (UK) Ltd (trading as Mylan)	Opposition rejected

US patents provide insights into the exclusivity only within the United States, but Movantik is protected by patents in multiple countries. Understanding the full scope of patent protection is crucial in strategizing market entry. By looking at the broader patent landscape, you can identify markets with weaker patent protection which could be ideal generic entry points. The following section offers details on Movantik's family patents as well as insights into ongoing legal events on those patents.

Movantik's family patents

Movantik has patent protection in a total of 43 countries. It's US patent count contributes only to 18.2% of its total global patent coverage. 9 countries have all of their patents expired or invalidated which has opened up potential generic launch opportunities in these countries. Click below to unlock the full patent family tree for Movantik.

Full family tree

Coming Soon

Patent Strength Analyzer

Will this be useful for you?

YesNo

Thank you for your response 🥳

Generic Launch

About Movantik

Movantik is a drug owned by Valinor Pharma Llc. It is used for managing constipation caused by opioid medications. Movantik uses Naloxegol Oxalate as an active ingredient. Movantik was launched by Valinor in 2014.